tiprankstipranks
KALA BIO (DE:27F)
FRANKFURT:27F
Germany Market

KALA BIO (27F) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

27F Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
KALA
BIO
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

27F Stock 12 Month Forecast

There Are No Analyst Ratings for DE:27F In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

27F Financial Forecast

27F Earnings Forecast

The previous quarter’s earnings for 27F were -€0.12.
The previous quarter’s earnings for 27F were -€0.12.

27F Sales Forecast

The previous quarter’s earnings for 27F were €0.00.
The previous quarter’s earnings for 27F were €0.00.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on DE:27F
Mizuho Securities
Mizuho Securities
€65.94
Hold
1839.52%
Upside
Downgraded
10/02/25
Kala Bio downgraded to Neutral from Outperform at MizuhoKala Bio downgraded to Neutral from Outperform at Mizuho
H.C. Wainwright Analyst forecast on DE:27F
H.C. Wainwright
H.C. Wainwright
Hold
Downgraded
09/29/25
Kala Bio downgraded to Neutral from Buy at H.C. WainwrightKala Bio downgraded to Neutral from Buy at H.C. Wainwright
Chardan Capital Analyst forecast on DE:27F
Chardan Capital
Chardan Capital
€659.44
Buy
19295.24%
Upside
Reiterated
08/11/25
Oppenheimer Remains a Buy on Kala Pharmaceuticals (KALA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on DE:27F
Mizuho Securities
Mizuho Securities
€65.94
Hold
1839.52%
Upside
Downgraded
10/02/25
Kala Bio downgraded to Neutral from Outperform at MizuhoKala Bio downgraded to Neutral from Outperform at Mizuho
H.C. Wainwright Analyst forecast on DE:27F
H.C. Wainwright
H.C. Wainwright
Hold
Downgraded
09/29/25
Kala Bio downgraded to Neutral from Buy at H.C. WainwrightKala Bio downgraded to Neutral from Buy at H.C. Wainwright
Chardan Capital Analyst forecast on DE:27F
Chardan Capital
Chardan Capital
€659.44
Buy
19295.24%
Upside
Reiterated
08/11/25
Oppenheimer Remains a Buy on Kala Pharmaceuticals (KALA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
ZURAZura Bio
TNYATenaya Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering KALA BIO

3 Months
Andreas ArgyridesChardan Capital
Success Rate
5/12 ratings generated profit
42%
Average Return
+35.47%
Copying Andreas Argyrides's trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of +35.47% per trade.
1 Year
Andreas ArgyridesChardan Capital
Success Rate
2/12 ratings generated profit
17%
Average Return
-44.57%
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -44.57% per trade.
2 Years
Andreas ArgyridesChardan Capital
Success Rate
2/12 ratings generated profit
17%
Average Return
-61.78%
Copying Andreas Argyrides's trades and holding each position for 2 Years would result in 16.67% of your transactions generating a profit, with an average return of -61.78% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

27F Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
0
0
0
0
In the current month, 27F has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 27F average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

27F Stock Forecast FAQ

What is DE:27F’s average 12-month price target, according to analysts?
Currently, no data Available
What is DE:27F’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for DE:27F, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is KALA BIO a Buy, Sell or Hold?
      Currently, no data Available
      What is KALA BIO’s share price target?
      Currently, no data Available
      What do analysts say about KALA BIO?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of KALA BIO?
      To buy shares of DE:27F, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.